Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athersys Inc ATHXQ

Healthcare Biotechnology
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage... see more

Recent & Breaking News (PINL:ATHXQ)

Athersys to Host First Quarter 2014 Financial Results Call

GlobeNewswire April 16, 2014

Athersys to Present at 2014 BIO Asia International Conference

GlobeNewswire March 26, 2014

Athersys Files Shelf Registration Statement to Replace Prior Shelf

GlobeNewswire March 13, 2014

Athersys Reports Fourth Quarter and 2013 Annual Results

GlobeNewswire March 13, 2014

Athersys to Present at Regen Med Investor Day March 26th in New York

GlobeNewswire March 7, 2014

Japan's Bold Initiative in Regenerative Medicine and Who the Big Winners Might Be

Accesswire March 3, 2014

Athersys to Host Fourth Quarter and Annual Financial Results Call

GlobeNewswire February 25, 2014

Regenerative Medicine Finally Gets Some Respect: Reni Benjamin

Equities.com February 13, 2014

Athersys to Present at BIO CEO & Investor Conference

Globe Newswire February 3, 2014

Companies Aligned to Capitalize on New Japanese Regenerative Medicine Initiatives

Accesswire January 13, 2014

Athersys Prices Registered Direct Offering of Common Stock and Warrants

Globe Newswire January 10, 2014

Athersys, Inc. CEO Gil Van Bokkelen to Be Interviewed on Clear Channel Business Talk Radio DFW 1190AM

Marketwired January 9, 2014

Athersys Announces New Patents in Japan for Stem Cell and Regenerative Medicine Technology

Globe Newswire January 9, 2014

Obesity Stock Plays Standing Out from the Crowd

Accesswire December 20, 2013

Athersys Confirms Completion of Patient Enrollment of Pfizer's Phase II Study of MultiStem(R) Cell Therapy for Ulcerative Colitis

Globe Newswire December 19, 2013

Athersys' MultiStem(R) Stem Cell Therapy Receives Orphan Drug Designation in Europe for Prevention of Graft-Versus-Host Disease

Globe Newswire December 17, 2013

Athersys Prices Registered Direct Offering of Common Stock and Warrants

Globe Newswire November 27, 2013

CORRECTION: Athersys to Present at 25th Annual Piper Jaffray Healthcare Conference

Globe Newswire November 25, 2013

Athersys to Present at 25th Annual Piper Jaffray Healthcare Conference

Globe Newswire November 25, 2013

Five Star Equities Issues New Research Reports on ATHX, CECO, ENT and OTIV

Accesswire November 22, 2013